Company intelligence / Profile preview

LignaMed, LLC

Philadelphia, Pennsylvania, United Stateslignamed.com ↗

Ownership: Private
Development stage: Preclinical

Overview

LignaMed’s lead candidate, LGM2605, is a novel oral small molecule synthetic lignan with anti-inflammatory and antioxidant properties. Preclinical data demonstrated efficacy in reducing airway hyperreactivity and improving lung function in models of Th2-low asthma—a subtype resistant to glucocorticoids. The compound has shown promise for other indications such as organ transplant viability and fibrosis. As of late 2019, the company was preparing for clinical development.

Therapeutic areas: OtherPulmonologyImmunology
Modalities: Small molecules (specifically synthetic lignans)
Industry: Biotech

Drug pipeline

1 asset

LGM2605

Preclinical

Partnerships

Exclusive licenses from The Trustees of the University of Pennsylvania and The Scripps Institute for patents covering LGM2605

Beyond the preview

Go deeper on LignaMed, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LignaMed, LLC.

Explore the full profile